MTI
Pharmaceutical company · 24 brands · 24 molecules
Ranked #219 of 311 companies in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)
Company overview
MTI is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 24 product registrations across 24 distinct molecules. Its portfolio is concentrated in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) and Other Beta-Lactam, Cephalosporins & Penems. DRAP has issued 1 alert involving its products.
Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.
Products by MTI
5 products matched in our catalogue — each with its observed price and DRAP approved ceiling.
Price ceiling age
DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.
Top molecules by brand count
Therapeutic classes
Price band (DRAP official ceilings)
Regulatory record
1 alert in the DRAP feed we track.
Competitive set
Companies whose registered portfolio overlaps most with this one.
Portfolio whitespace
Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.
Get the full profile for MTI
This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.
Request this brief See what’s included